Enzeevu (aflibercept-abzv)

Where it stands

According to the official records, Enzeevu (aflibercept-abzv), from Sandoz Inc, is approved in the US. The FDA approval is dated 2026-10-22 and is recorded as a single milestone from an official source. It is listed as a biosimilar, an injectable, under BLA761382.

The records leave several fields empty: therapeutic area, indication, and CHMP opinion date. A CHMP date is not expected for a US-only record. The approved indication, strength, presentation and dosing regimen are not given, so this analysis cannot describe the clinical use of the product or the scope of its label.

Regulatory pathway and designations

The only designation recorded is Biosimilar. In the US, biosimilars are generally approved through the abbreviated 351(k) pathway under the Public Health Service Act. Under this pathway, a sponsor shows that its product is highly similar to an FDA-licensed reference product, with no clinically meaningful differences in safety, purity and potency. It does not repeat the full clinical development program of the originator. The BLA number (761382) is consistent with a biologics application, and the four-letter suffix in the nonproprietary name (-abzv) follows FDA's naming convention for biological products.

The records do not name the reference product, and they do not say whether the FDA has designated Enzeevu as interchangeable with it. Interchangeability is a separate determination from biosimilarity, so it should not be assumed. The records also do not include any orphan, fast-track or other expedited designation, and they give no review timeline, advisory committee activity or PDUFA/BsUFA goal date.

Safety and pharmacovigilance

The records contain no safety information: no label warnings, adverse event data, immunogenicity findings, REMS or postmarketing commitments. Any comment on the product's specific safety profile would therefore go beyond the data provided.

As general background, an approved biosimilar is subject to the same postmarketing pharmacovigilance expectations as other biologics. These include adverse event reporting, periodic safety reporting, and labeling updates when new information emerges. Immunogenicity is typically a focus of biosimilar monitoring. Professionals should review the approved prescribing information and the FDA approval package once available to see what safety monitoring applies to this product.

What to watch

The first step is to get the approved label and review documents. They will confirm the indications, the reference product, the presentations, and any interchangeability status. Those details are missing from the current records and determine the product's practical scope.

Beyond that, the records are silent on commercial launch timing and on any patent or exclusivity issues that might affect it, so no view can be offered here. Useful items to track are the FDA's Purple Book listing, any later labeling supplements, and any Sandoz announcements on availability. The same applies to any later regulatory filings for this product in other regions, which are not covered by these records.